Retatrutide (GLP-1 R): A Research Peptide Overview

Retatrutide — listed in our catalog as GLP-1 R — is the newest and most mechanistically complex compound in the incretin research family. This overview explains its triple-agonist mechanism, formats, and place alongside semaglutide and tirzepatide.

What is retatrutide?

Retatrutide is a synthetic peptide studied as a triple GLP-1 / GIP / glucagon receptor agonist. Engaging three receptor pathways simultaneously makes it a focus of advanced metabolic and receptor-pathway research.

Research pathways

  • Triple GLP-1 / GIP / glucagon receptor signaling research.
  • Energy-metabolism and glucose-regulation research models.
  • Comparative incretin research against dual- and single-agonist compounds.

Formats & doses

GLP-1 R is available in lyophilized vials from 10 mg up to 50 mg, plus pre-reconstituted activated solutions:

See all options in the GLP-1 research series.

Where it sits in the incretin family

Think of the incretin compounds as a ladder of receptor targets: semaglutide (GLP-1 only) → tirzepatide (GLP-1 + GIP) → retatrutide (GLP-1 + GIP + glucagon). For the dual-agonist comparison, read our tirzepatide overview.

Handling, reconstitution & purity

Reconstitute lyophilized vials with bacteriostatic water per our reconstitution guide. All material is ≥98% HPLC-verified, documented on the Quality & COA page.

Manufacturing & Quality

Alpha Biologix manufactures GLP-1 R (retatrutide) under pharmaceutical-grade manufacturing standards. Each batch is verified to ≥98% HPLC purity and independently tested by third-party laboratories, with a Certificate of Analysis (COA) available per batch for full research traceability.

All products and information are provided for laboratory and research use only. Not for human or veterinary use, diagnostic, or therapeutic application. No medical claims are made.

Back to blog